Prestige Consumer Healthcare Inc.’s fiscal 2021, ended on 31 March, benefited from the company’s strategic focus during the pandemic on health conditions that consumers may be more inclined than ever to treat at home without a doctor’s visit.
Prestige Consumer’s ‘Nimble’ Marketing Helps Beat Fiscal 2021 Guidance
Less travel, closed schools and a slower cold/cough season during the pandemic required Prestige Consumer to invest strategically across its OTC healthcare portfolio in fiscal 2021. Dramamine motion sickness and Nix head lice treatments got less attention, while Monistat, Compound W and Clear Eyes received more.
